researchers retrospectively analyzed the cineangiograms of 350 patients with multivessel coronary artery disease who had been studied consecutively at each of four participating centers; they then stratified them according to lesion type. More than 70% of the patients had severe angina, and the vast majority (78%) had two-vessel coronary disease. Only 30% of the population had type A lesions, whereas 61% had lesion characteristics for which the success rates were in the 60-80% range (type B); 10% of the patients had type C lesions. This case mix underscores the reality of angioplasty, namely, the majority of patients undergoing the procedure have complex disease.
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The major contribution of this labor-intensive study is the demonstration that both the procedural success and complication rates (death, myocardial infarction, or emergency bypass surgery) of percutaneous transluminal coronary angioplasty (PTCA) can be predicted with good accuracy by careful assessment of lesion morphology. Using the ACC/AHA lesion-specific classification, the authors found a 92% success rate and a 2% complication rate for type A lesions, 80% success and 7% complication rates for type B lesions, and 61% success and 10% complication rates for type C lesions. Of importance, the study group found this classification somewhat lacking in discriminating risk among the most frequently encountered patient group -those with type B lesions. By further stratifying this group into those with type Bi or B2 lesions, they refined their predictive ability such that type B1 (one type B characteristic) lesions had a success rate of 84% with a complication rate of 4%. For patients with type B2 lesions (two or more type B characteristics), the success rate decreased to 76% and the complication rate increased to 10%.
It is emphasized that these researchers conclude that patients with type B2 or C lesions should be seriously considered for surgical revascularization in lieu of PTCA. This translates to 37% of a population routinely accepted for coronary angioplasty at four major US medical centers during 1986-1987. This Ryan Estimating Success of Multivessel Angioplasty 1517 recommendation probably also portends a substantial shift in the number of patients referred directly for bypass surgery in the near future.
This study offers many additional observations that should influence the selection and screening processes for angioplasty procedures. Diabetes, for example, was the sole clinical feature to be independently predictive of procedural outcome; diabetic patients had a 74% procedural success rate compared with an 87% rate for nondiabetic patients, and they experienced major ischemic complications 2.6-fold more frequently. Although previous studies have identified lesion characteristics that predispose to complications,3-5 it is rather sobering to realize that a bend stenosis carries a 34% major complication rate but only a 55% likelihood of successful dilation. It is also of interest that high-grade stenoses of 80% diameter narrowing or greater have a sub par success rate of 73%. These "tight" lesions are often viewed as ideal for balloon dilation, particularly when they occur as the only lesion in one-vessel disease.
Certain trends have been occurring in the field of angioplasty for some time now, and the current report from the multicenter MAPS group provides interesting insights into these trends. First, patients with "multivessel disease" in this series mainly comprised patients with two-vessel disease (78% of the study population), an incidence rate that is not dissimilar from those of other reports relating to multilesion disease in the angioplasty literature.6 Clearly, although this group of patients frequently warrants revascularization because of unstable or severe symptoms, they are known to have a more favorable long-term outcome than patients with three-vessel disease. This becomes an important consideration in any comparison study of surgery versus angioplasty in the revascularization of patients with multivessel disease because most surgical series comprise patients with three-vessel disease. It also reinforces a sense that the burgeoning business of multivessel angioplasty primarily involves the "two-vessel disease market."
A clinically important, it is evident that at least one third of patients who undergo PTCA are incompletely revascularized. If so, it leads to the inescapable conclusion that multivessel angioplasty will probably never achieve the long-term benefits of bypass surgery. For now, however, it seems reasonable to consider the procedure an appropriate intermediate step in the care of symptomatic patients with coronary disease.
I add a note of caution in interpreting the report of the MAPS group. First, this is a retrospective evaluation of lesion morphology, and there is no guarantee that these characteristics will have the same predictive value in an individual patient. Validation of this schema using a prospective study design becomes critically important. Second, there is a rather obvious flaw in the present study, and it relates to the exceedingly high interobserver variability in interpreting morphological characteristics of specific lesions. There was a 42% disagreement in classifying the 57 lesions randomly selected for such analysis. Also, the important question of intraobserver variability was not tested in this study. This is likely to have great relevance in the reproducibility of angiographic readings that are considerably influenced by such factors as proper frame and view selection, judging of end diastole, and distinguishing true from functional lumen. Because even sophisticated computers capable of digital analyses are limited by some of these variables, angiographic interpretation will probably remain a qualitative science. If the state-ofthe-art is such that the definition of morphological lesion characteristics is flawed by a high interobserver/intraobserver variability, we will have to acknowledge the limitations of this promising route for proper patient selection and promptly find better methods of defining lesion morphology. Intravascular imaging using ultrasound may, for example, prove more valuable in this regard.
Notwithstanding, the MAPS report is a critical piece of retrospective analysis that brings into focus some very specific morphological and clinical features that clearly influence procedural success. At the very least, this study should stimulate research that seeks to improve current methods of imaging, defining, and analyzing coronary artery lesions. It also sets the stage for determining what factors influence long-term success after angioplasty. It is virtually certain that procedural success, and thus lesion morphology, will have a similar bearing on long-term outcome. It also seems logical to forecast that complete revascularization will surface as an important variable for long-term relief of symptoms.
Such conjecture, however, merely underscores how very much our understanding of angioplasty and its future role depends on the outcome of ongoing randomized clinical trials comparing results of PTCA with those of surgery in patients with multivessel disease (Table 1) . It is anticipated, among other things, that the National Heart, Lung, and Blood Institute Bypass Angioplasty Revascularization Intervention (BARI) trial will amply test the threevessel disease cohort as well as the two-vessel disease 4 "market"; all of the studies should provide comparison data relative to "completeness of revascularization" and its importance, if any, in similar patients. Accordingly, it would seem incumbent on the clinical community to put aside its biases and enthusiastically enroll all eligible patients in these critically important trials as they enter their final stages of recruitment.
